세계의 나잘 코르티코스테로이드 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Nasal Corticosteroids Market - Scope of Report

TMR's report on the global nasal corticosteroids market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global nasal corticosteroids market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global nasal corticosteroids market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the nasal corticosteroids market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global nasal corticosteroids market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global nasal corticosteroids market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global nasal corticosteroids market.

The report delves into the competitive landscape of the global nasal corticosteroids market. Key players operating in the global nasal corticosteroids market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global nasal corticosteroids market profiled in this report.

Key Questions Answered in Global nasal corticosteroids Market Report:

• What is the sales/revenue generated by nasal corticosteroids across all regions during the forecast period?
• What are the opportunities in the global nasal corticosteroids market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Nasal Corticosteroids Market - Research Objectives and Research Approach

The comprehensive report on the global nasal corticosteroids market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global nasal corticosteroids market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global nasal corticosteroids market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nasal Corticosteroids Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Nasal Corticosteroids Market Analysis and Forecast, 2020-2034

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Nasal Corticosteroids Market Analysis and Forecast, by Drug Type

• 6.1. Introduction and Definitions
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Drug Type, 2020-2034
  • 6.3.1. Fluticasone Propionate
  • 6.3.2. Budesonide
  • 6.3.3. Beclomethasone Dipropionate
  • 6.3.4. Mometasone Furoate
  • 6.3.5. Triamcinolone Acetonide
  • 6.3.6. Ciclesonide
  • 6.3.7. Flunisolide
  • 6.3.8. Tixocortol
• 6.4. Market Attractiveness, by Drug Type

7. Global Nasal Corticosteroids Market Analysis and Forecast, by Indication Type

• 7.1. Introduction and Definitions
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Indication Type, 2020-2034
  • 7.3.1. Allergic Rhinitis (AR)
    • 7.3.1.1. Seasonal AR
    • 7.3.1.2. Perennial AR
  • 7.3.2. Non-allergic Rhinitis (NAR)
    • 7.3.2.1. Infectious NAR
    • 7.3.2.2. Vasomotor NAR
    • 7.3.2.3. Atropic NAR
• 7.4. Market Attractiveness, by Indication Type

8. Global Nasal Corticosteroids Market Analysis and Forecast, By Type

• 8.1. Introduction and Definitions
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, By Type, 2020-2034
  • 8.3.1. Prescription Drugs
  • 8.3.2. Over-the-Counter Drugs
• 8.4. Market Attractiveness, By Type

9. Global Nasal Corticosteroids Market Analysis and Forecast, by Dosage Form

• 9.1. Introduction and Definitions
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by Dosage Form, 2020-2034
  • 9.3.1. Intranasal Drops
  • 9.3.2. Intranasal Sprays
• 9.4. Market Attractiveness, by Dosage Form

10. Global Nasal Corticosteroids Market Analysis and Forecast, by Distribution Channel

• 10.1. Introduction and Definitions
• 10.2. Key Findings/Developments
• 10.3. Market Value Forecast, by Distribution Channel, 2020-2034
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Online Pharmacies
• 10.4. Market Attractiveness, by Distribution Channel

11. Global Nasal Corticosteroids Market Analysis and Forecast, by Region

• 11.1. Key Findings
• 11.2. Market Value Forecast, by Region, 2020-2034
  • 11.2.1. North America
  • 11.2.2. Europe
  • 11.2.3. Asia Pacific
  • 11.2.4. Latin America
  • 11.2.5. Middle East & Africa
• 11.3. Market Attractiveness, by Region

12. North America Nasal Corticosteroids Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Drug Type, 2020-2034
  • 12.2.1. Fluticasone Propionate
  • 12.2.2. Budesonide
  • 12.2.3. Beclomethasone Dipropionate
  • 12.2.4. Mometasone Furoate
  • 12.2.5. Triamcinolone Acetonide
  • 12.2.6. Ciclesonide
  • 12.2.7. Flunisolide
  • 12.2.8. Tixocortol
• 12.3. Market Attractiveness, by Drug Type
• 12.4. Market Value Forecast, by Indication Type, 2020-2034
  • 12.4.1. Allergic Rhinitis (AR)
    • 12.4.1.1. Seasonal AR
    • 12.4.1.2. Perennial AR
  • 12.4.2. Non-allergic Rhinitis (NAR)
    • 12.4.2.1. Infectious NAR
    • 12.4.2.2. Vasomotor NAR
    • 12.4.2.3. Atropic NAR
• 12.5. Market Attractiveness, by Indication Type
• 12.6. Market Value Forecast, By Type, 2020-2034
  • 12.6.1. Prescription Drugs
  • 12.6.2. Over-the-Counter Drugs
• 12.7. Market Attractiveness, By Type
• 12.8. Market Value Forecast, by Dosage Form, 2020-2034
  • 12.8.1. Intranasal Drops
  • 12.8.2. Intranasal Sprays
• 12.9. Market Attractiveness, by Dosage Form
• 12.10. Market Value Forecast, by Distribution Channel, 2020-2034
  • 12.10.1. Hospital Pharmacies
  • 12.10.2. Retail Pharmacies
  • 12.10.3. Online Pharmacies
• 12.11. Market Attractiveness, by Distribution Channel
• 12.12. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 12.12.1. U.S.
  • 12.12.2. Canada
• 12.13. Market Attractiveness Analysis
  • 12.13.1. By Drug Type
  • 12.13.2. By Indication Type
  • 12.13.3. By Type
  • 12.13.4. By Dosage Form
  • 12.13.5. By Distribution Channel
  • 12.13.6. By Country

13. Europe Nasal Corticosteroids Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Drug Type, 2020-2034
  • 13.2.1. Fluticasone Propionate
  • 13.2.2. Budesonide
  • 13.2.3. Beclomethasone Dipropionate
  • 13.2.4. Mometasone Furoate
  • 13.2.5. Triamcinolone Acetonide
  • 13.2.6. Ciclesonide
  • 13.2.7. Flunisolide
  • 13.2.8. Tixocortol
• 13.3. Market Attractiveness, by Drug Type
• 13.4. Market Value Forecast, by Indication Type, 2020-2034
  • 13.4.1. Allergic Rhinitis (AR)
    • 13.4.1.1. Seasonal AR
    • 13.4.1.2. Perennial AR
  • 13.4.2. Non-allergic Rhinitis (NAR)
    • 13.4.2.1. Infectious NAR
    • 13.4.2.2. Vasomotor NAR
    • 13.4.2.3. Atropic NAR
• 13.5. Market Attractiveness, by Indication Type
• 13.6. Market Value Forecast, By Type, 2020-2034
  • 13.6.1. Intranasal Drops
  • 13.6.2. Intranasal Sprays
• 13.7. Market Attractiveness, By Type
• 13.8. Market Value Forecast, by Dosage Form, 2020-2034
  • 13.8.1. Companion Animal
  • 13.8.2. Livestock Animal
• 13.9. Market Attractiveness, by Dosage Form
• 13.10. Market Value Forecast, by Distribution Channel, 2020-2034
  • 13.10.1. Hospital Pharmacies
  • 13.10.2. Retail Pharmacies
  • 13.10.3. Online Pharmacies
• 13.11. Market Attractiveness, by Distribution Channel
• 13.12. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 13.12.1. Germany
  • 13.12.2. U.K.
  • 13.12.3. France
  • 13.12.4. Italy
  • 13.12.5. Spain
  • 13.12.6. Rest of Europe
• 13.13. Market Attractiveness Analysis
  • 13.13.1. By Drug Type
  • 13.13.2. By Indication Type
  • 13.13.3. By Type
  • 13.13.4. By Dosage Form
  • 13.13.5. By Distribution Channel
  • 13.13.6. By Country/Sub-region

14. Asia Pacific Nasal Corticosteroids Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Drug Type, 2020-2034
  • 14.2.1. Fluticasone Propionate
  • 14.2.2. Budesonide
  • 14.2.3. Beclomethasone Dipropionate
  • 14.2.4. Mometasone Furoate
  • 14.2.5. Triamcinolone Acetonide
  • 14.2.6. Ciclesonide
  • 14.2.7. Flunisolide
  • 14.2.8. Tixocortol
• 14.3. Market Attractiveness, by Drug Type
• 14.4. Market Value Forecast, by Indication Type, 2020-2034
  • 14.4.1. Allergic Rhinitis (AR)
    • 14.4.1.1. Seasonal AR
    • 14.4.1.2. Perennial AR
  • 14.4.2. Non-allergic Rhinitis (NAR)
    • 14.4.2.1. Infectious NAR
    • 14.4.2.2. Vasomotor NAR
    • 14.4.2.3. Atropic NAR
• 14.5. Market Attractiveness, by Indication Type
• 14.6. Market Value Forecast, By Type, 2020-2034
  • 14.6.1. Prescription Drugs
  • 14.6.2. Over-the-Counter Drugs
• 14.7. Market Attractiveness, By Type
• 14.8. Market Value Forecast, by Dosage Form, 2020-2034
  • 14.8.1. Intranasal Drops
  • 14.8.2. Intranasal Sprays
• 14.9. Market Attractiveness, by Dosage Form
• 14.10. Market Value Forecast, by Distribution Channel, 2020-2034
  • 14.10.1. Hospital Pharmacies
  • 14.10.2. Retail Pharmacies
  • 14.10.3. Online Pharmacies
• 14.11. Market Attractiveness, by Distribution Channel
• 14.12. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 14.12.1. China
  • 14.12.2. Japan
  • 14.12.3. India
  • 14.12.4. Australia & New Zealand
  • 14.12.5. Rest of Asia Pacific
• 14.13. Market Attractiveness Analysis
  • 14.13.1. By Drug Type
  • 14.13.2. By Indication Type
  • 14.13.3. By Type
  • 14.13.4. By Dosage Form
  • 14.13.5. By Distribution Channel
  • 14.13.6. By Country/Sub-region

15. Latin America Nasal Corticosteroids Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Drug Type, 2020-2034
  • 15.2.1. Fluticasone Propionate
  • 15.2.2. Budesonide
  • 15.2.3. Beclomethasone Dipropionate
  • 15.2.4. Mometasone Furoate
  • 15.2.5. Triamcinolone Acetonide
  • 15.2.6. Ciclesonide
  • 15.2.7. Flunisolide
  • 15.2.8. Tixocortol
• 15.3. Market Attractiveness, by Drug Type
• 15.4. Market Value Forecast, by Indication Type, 2020-2034
  • 15.4.1. Allergic Rhinitis (AR)
    • 15.4.1.1. Seasonal AR
    • 15.4.1.2. Perennial AR
  • 15.4.2. Non-allergic Rhinitis (NAR)
    • 15.4.2.1. Infectious NAR
    • 15.4.2.2. Vasomotor NAR
    • 15.4.2.3. Atropic NAR
• 15.5. Market Attractiveness, by Indication Type
• 15.6. Market Value Forecast, By Type, 2020-2034
  • 15.6.1. Prescription Drugs
  • 15.6.2. Over-the-Counter Drugs
• 15.7. Market Attractiveness, By Type
• 15.8. Market Value Forecast, by Dosage Form, 2020-2034
  • 15.8.1. Intranasal Drops
  • 15.8.2. Intranasal Sprays
• 15.9. Market Attractiveness, by Dosage Form
• 15.10. Market Value Forecast, by Distribution Channel, 2020-2034
  • 15.10.1. Hospital Pharmacies
  • 15.10.2. Retail Pharmacies
  • 15.10.3. Online Pharmacies
• 15.11. Market Attractiveness, by Distribution Channel
• 15.12. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 15.12.1. Brazil
  • 15.12.2. Mexico
  • 15.12.3. Rest of Latin America
• 15.13. Market Attractiveness Analysis
  • 15.13.1. By Drug Type
  • 15.13.2. By Indication Type
  • 15.13.3. By Type
  • 15.13.4. By Dosage Form
  • 15.13.5. By Distribution Channel
  • 15.13.6. By Country/Sub-region

16. Middle East & Africa Nasal Corticosteroids Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast, by Drug Type, 2020-2034
  • 16.2.1. Fluticasone Propionate
  • 16.2.2. Budesonide
  • 16.2.3. Beclomethasone Dipropionate
  • 16.2.4. Mometasone Furoate
  • 16.2.5. Triamcinolone Acetonide
  • 16.2.6. Ciclesonide
  • 16.2.7. Flunisolide
  • 16.2.8. Tixocortol
• 16.3. Market Attractiveness, by Drug Type
• 16.4. Market Value Forecast, by Indication Type, 2020-2034
  • 16.4.1. Allergic Rhinitis (AR)
    • 16.4.1.1. Seasonal AR
    • 16.4.1.2. Perennial AR
  • 16.4.2. Non-allergic Rhinitis (NAR)
    • 16.4.2.1. Infectious NAR
    • 16.4.2.2. Vasomotor NAR
    • 16.4.2.3. Atropic NAR
• 16.5. Market Attractiveness, by Indication Type
• 16.6. Market Value Forecast, By Type, 2020-2034
  • 16.6.1. Prescription Drugs
  • 16.6.2. Over-the-Counter Drugs
• 16.7. Market Attractiveness, By Type
• 16.8. Market Value Forecast, by Dosage Form, 2020-2034
  • 16.8.1. Intranasal Drops
  • 16.8.2. Intranasal Sprays
• 16.9. Market Attractiveness, by Dosage Form
• 16.10. Market Value Forecast, by Distribution Channel, 2020-2034
  • 16.10.1. Hospital Pharmacies
  • 16.10.2. Retail Pharmacies
  • 16.10.3. Online Pharmacies
• 16.11. Market Attractiveness, by Distribution Channel
• 16.12. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 16.12.1. GCC Countries
  • 16.12.2. South Africa
  • 16.12.3. Rest of Middle East & Africa
• 16.13. Market Attractiveness Analysis
  • 16.13.1. By Drug Type
  • 16.13.2. By Indication Type
  • 16.13.3. By Type
  • 16.13.4. By Dosage Form
  • 16.13.5. By Distribution Channel
  • 16.13.6. By Country/Sub-region

17. Competition Landscape

• 17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 17.2. Market Share Analysis, by Company (2023)
• 17.3. Company Profiles
  • 17.3.1. Merck & Co., Inc.
    • 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.1.2. Product Portfolio
    • 17.3.1.3. Financial Overview
    • 17.3.1.4. SWOT Analysis
    • 17.3.1.5. Strategic Overview
  • 17.3.2. GSK plc
    • 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.2.2. Product Portfolio
    • 17.3.2.3. Financial Overview
    • 17.3.2.4. SWOT Analysis
    • 17.3.2.5. Strategic Overview
  • 17.3.3. AstraZeneca
    • 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.3.2. Product Portfolio
    • 17.3.3.3. Financial Overview
    • 17.3.3.4. SWOT Analysis
    • 17.3.3.5. Strategic Overview
  • 17.3.4. Sanofi S.A.
    • 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.4.2. Product Portfolio
    • 17.3.4.3. Financial Overview
    • 17.3.4.4. SWOT Analysis
    • 17.3.4.5. Strategic Overview
  • 17.3.5. Perrigo Company plc
    • 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.5.2. Product Portfolio
    • 17.3.5.3. Financial Overview
    • 17.3.5.4. SWOT Analysis
    • 17.3.5.5. Strategic Overview
  • 17.3.6. Teva Pharmaceutical Industries Ltd.
    • 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.6.2. Product Portfolio
    • 17.3.6.3. Financial Overview
    • 17.3.6.4. SWOT Analysis
    • 17.3.6.5. Strategic Overview
  • 17.3.7. Glenmark Pharmaceuticals Limited
    • 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.7.2. Product Portfolio
    • 17.3.7.3. Financial Overview
    • 17.3.7.4. SWOT Analysis
    • 17.3.7.5. Strategic Overview
  • 17.3.8. Mylan N.V.
    • 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.8.2. Product Portfolio
    • 17.3.8.3. Financial Overview
    • 17.3.8.4. SWOT Analysis
    • 17.3.8.5. Strategic Overview
  • 17.3.9. Novartis AG
    • 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.9.2. Product Portfolio
    • 17.3.9.3. Financial Overview
    • 17.3.9.4. SWOT Analysis
    • 17.3.9.5. Strategic Overview
  • 17.3.10. Pfizer Inc.
    • 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.10.2. Product Portfolio
    • 17.3.10.3. Financial Overview
    • 17.3.10.4. SWOT Analysis
    • 17.3.10.5. Strategic Overview
  • 17.3.11. Pharmascience Inc.
    • 17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.11.2. Product Portfolio
    • 17.3.11.3. Financial Overview
    • 17.3.11.4. SWOT Analysis
    • 17.3.11.5. Strategic Overview